Highlights Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME Other stock markets 11:41:15 2026-01-16 am EST			5-day change	1st Jan Change
10.89 ^EUR	-2.85%		-4.39%	+1.78%

Jan. 16	Spanish stocks - Factors to watch on Jan 16	RE
Jan. 15	European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading	MT

Highlights

Dec. 19	Grifols Wins US FDA Approval for Rare Blood Disorder Drug Fesilty	MT
Dec. 19	Grifols gets FDA approval for new fibrinogen concentrate, Fesiltytm	RE
Dec. 19	Biotest AG Announces US FDA Approval of Grifols' Fesilty?? (fibrinogen, Human-Chmt)	CI
Dec. 16	European Medicines Agency Grants Compliance Certification for Plasma Supplied by Grifols Egypt	MT
Dec. 16	Grifols gets EMA approval for manufacture and selling of Egyptian plasma	RE
Nov. 18	Grifols gets FDA approval for Thrombate III in pediatric patients in U.S.	RE
Nov. 13	Grifols gets regulatory approval for fibrinogen concentrate in Germany	RE
Nov. 04	Rigel Pharma beats Q3 revenue estimates; lifts annual rev outlook	RE
Nov. 04	Grifols Q3 net profit 127 mln euros	RE
25-10-09	Spanish court summons Gotham City founder in Grifols share price probe	RE
25-08-10	Ex-dividend day for interim dividend	FA
25-08-07	Spain's CNMV fines Grifols and several board members total of 1.36 mln euros	RE
25-07-31	BofA Keeps Grifols at Buy as Strong Q2 Offsets Currency Headwinds	MT
25-07-29	Grifols, S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-07-29	Grifols, S.A. Announces Interim Dividend for the Year 2025, Payable on 13 August 2025	CI
25-07-29	Grifols Q2 Adjusted EBITDA, Revenue Rise; Dividend Payment Reinstated	MT
25-07-29	Grifols reaffirms 2025 guidance with improved FCF pre-M&A guidance	RE
25-07-29	Grifols to pay interim dividend of 0.15 eur/shr on Aug 13	RE
25-07-29	Grifols H1 net profit at 176.8 mln euros	RE
25-07-28	Astrazeneca, Other US-Listed Pharma Companies Seen Insulated From New EU Tariff Deal, Barclays Says	MT
25-06-19	Grifols Says Positive Fibrinogen Phase 3 Trial Results Published	RE
25-06-12	Grifols to Finalize Delisting Offer for Biotest	MT
25-06-11	Grifols Says Delisting Offer Accepted By 416,922 Ordinary Shares Of Biotest	RE
25-06-04	Biotest to Delist from Frankfurt Bourse	MT
25-05-30	US Court Allows Grifols' Defamation Suit Against Gotham City to Proceed	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Grifols lifts 2025 targets but fibrinogen delay and forex drag weigh on outlook

November 06, 2025 at 05:01 am EST